Brief: Annovis Bio Announces Completion Of Phase III Parkinson's Disease Treatment Enrollment At Record Pace
U.S. STOCKS ON THE MOVE-Nordstrom, Veeva Systems, Chewy
Annovis Bio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Annovis Bio Announces Q1 2023 Financial Results And Provides Corporate Update
Annovis Bio Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Annovis Bio Announces Issuance Of U.S. Patent Covering The Use Of Lead Drug Candidate, Buntanetap
Brief: Annovis Bio Provides Updated Webcast Link & Dial-In Info R&D Webcast
Brief: Annovis Bio Announces Update On Recruitment Into Its Phase 2/3 Alzheimer's Study
Brief: Annovis Bio Raises Aggregate Gross Proceeds Of About $8.7 Million
Brief: Annovis Bio Announces Fourth Quarter Financial Results
Brief: Annovis Bio Enters Sales Agreement With BofA Securities
Brief: Annovis Bio Receives Interim Analysis For Sample Size Re-Estimation For Its Phase 3 Clinical Trial
U.S. STOCKS ON THE MOVE-Alibaba Group, TripAdvisor, MGM Resorts
U.S. STOCKS ON THE MOVE-Alphabet, Fox Corp, New York Times
Annovis Bio rises on clinical sites approval for Parkinson's disease study
Brief: Annovis Bio Announces Approval For European Union Clinical Trial Sites For Phase 3 Study Of Parkinson's Disease Drug Buntanetap
Annovis Bio files for patent covering use of lead drug; shares rise
Brief: Annovis Bio Announces Patient Enrollment Update For Phase 3 Study Of Buntanetap For The Treatment Of Parkinson's Disease
Brief: Annovis Bio Announces New Appointments To Its Senior Leadership Team